Back to News
Market Impact: 0.3
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Source: globenewswire.com
Healthcare & BiotechRegulation & Legislation
The UK MHRA authorized CAMP4 to initiate first-in-human studies of CMP-002, adding to recent trial clearances in Australia and Argentina. The regulatory progress enables broader early-stage clinical development for the candidate and is a positive milestone for CAMP4's pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
CAMP0.72
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- How This County Made the Data Center Boom Pay Off
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine